SUSMED INC

Company Overview

SUSMED Inc. is a Japanese digital-therapeutics developer. It develops prescription treatment apps and also sells clinical-trial and data-analysis systems to pharmaceutical companies, medical institutions, and researchers. Its principal commercial asset is Medcle, an insomnia-treatment app that entered Japan’s public reimbursement system and began sales on 1 June 2026.

Data freshness matters unusually much here. The latest clean official annual base is FY2025, ended 30 June 2025, filed on 26 September 2025. That audited annual filing reported revenue of ¥463.0 million, an operating loss of ¥299.5 million, a net loss of ¥298.4 million, and operating cash outflow of ¥432.5 million.

Newer full-year results for FY2026, ended 30 June 2026, were released on 7 August 2026, but the earnings release explicitly states that it was not audited; the annual securities filing was scheduled for 29 September 2026. FY2026 is therefore a full-year unaudited company earnings release, not a clean audited annual filing. It reported revenue of ¥497.2 million, operating loss of ¥330.2 million, net loss of ¥382.7 million, operating cash outflow of ¥474.5 million, and free-cash-flow outflow of ¥702.6 million including investing cash outflows.

Current market data supplied for 7 September 2026 show a share price of ¥404 and market capitalization of ¥6.81 billion. The FY2026 unaudited balance sheet reported cash and deposits of ¥3.70 billion and total liabilities of ¥148 million. Interest-bearing debt was not separately identified in the supplied materials; the deterministic snapshot correctly classifies net cash as unavailable rather than zero. A conservative calculation that deducts all reported liabilities from cash produces a ¥3.55 billion net-liquidity proxy; that is an analyst calculation, not a reported net-cash figure.

This is not a profitable software compounder temporarily priced like a distressed value stock. It is a cash-backed, loss-making medical-technology venture whose equity value depends on whether Medcle and the pipeline can become repeatable commercial products before the cash reserve is depleted.

How the Company Makes Money

SUSMED has two economic engines. The first is the DTx product business: it develops regulated therapeutic apps, enters partnerships with drug companies, receives milestone payments when clinical or regulatory conditions are met, and seeks royalties or direct sales revenue once a product launches. Medcle is the first meaningful test of whether that model can generate recurring revenue rather than development-stage receipts.

The second is the DTx platform business: SourceDataSync, a blockchain-enabled clinical-trial system, and a machine-learning analysis system are offered to third parties. This business should be less binary than therapeutic-app development because it can produce recurring project or usage revenue. Its FY2026 revenue was ¥157.0 million, versus ¥163.0 million in FY2025: stable, but not yet evidence of a rapidly scaling software franchise.

FY2026 segment figures show the distinction clearly. The DTx product segment recorded ¥340.2 million of revenue and ¥103.4 million of segment profit, while the platform segment recorded ¥157.0 million of revenue and ¥77.0 million of segment profit. However, the product segment’s revenue was substantially explained by a ¥240 million tinnitus-app milestone and a ¥100 million premenstrual-symptom-app milestone. Those payments are economically useful but are not recurring customer demand. Aggregate segment profit was overwhelmed by research, selling, administration, and corporate costs, producing the ¥330.2 million company-wide operating loss.

The business is asset-light in the conventional physical-capex sense, but it is capital-intensive in the economically relevant sense: clinical research, regulatory work, medical evidence, commercialization, and specialist staffing consume cash before a product reaches scale. FY2026 research and development expense was ¥247.5 million, and the company’s FY2027 guidance calls for another loss while raising investment in development. Stock-based compensation is also material: FY2026 operating cash flow included ¥84.1 million of stock-compensation expense. It is a real employee cost and should not be added back as though it were free.

The potentially durable assets are clinical evidence, regulatory approvals, reimbursement access, partner relationships, and credibility with medical providers. The fragile assets are the software itself and the commercial model. A well-funded competitor can reproduce an app or clinical-trial software platform much faster than it can reproduce clinical evidence, reimbursement status, and physician adoption. SUSMED has elements of a regulated franchise, but it has not yet demonstrated the recurring returns on capital that would justify calling it a high-return compounder.

Why the Stock Fell

The dominant recent catalyst was the 26 August 2026 announcement that SUSMED and Shionogi had agreed to terminate their exclusive sales agreement for Medcle. The next trading day, the stock reportedly reached its daily lower price limit. The supplied market snapshot, dated 7 September 2026, shows the shares at ¥404. A complete verified price series was not supplied, so the precise decline from any earlier high should not be attributed to one event alone.

The economic significance of the announcement is clearer than management’s characterization of the near-term accounting effect. SUSMED will receive a confirmed ¥200 million reimbursement-related milestone in FY2027 first-quarter revenue, and it retains all future direct Medcle sales revenue. But it loses Shionogi’s exclusive-sales relationship, has no announced continuing cooperation with Shionogi for Medcle, and will not receive the remaining contractual milestones.

The terminated contract had originally disclosed total potential milestones of up to ¥4.7 billion. Before the termination, ¥0.6 billion had been received; the newly confirmed ¥0.2 billion remains payable. The theoretical maximum conditional milestone amount that will no longer be available is therefore up to ¥3.9 billion. This is not a ¥3.9 billion loss of booked assets: the probability, timing, and conditions of those milestones were never disclosed. It is nevertheless a real loss of contingent upside and a signal that the product’s commercial path is less validated than the market had hoped.

A second source of pressure is the FY2027 company guidance released on 7 August 2026: revenue of ¥838 million but an operating loss of ¥461 million and net loss of ¥541 million. The company is guiding to higher revenue and a deeper loss. That tells the market that commercialization and pipeline spending will absorb more cash before profitability, not less.

A third observed item is ownership activity. SPARX Asset Management’s large-shareholding filing on 31 August 2026 reported a reduction from 5.16% to 4.00%. This is evidence of a seller, not evidence of inside knowledge or the cause of the broader decline.

What the Market Is Assuming

The market is not valuing SUSMED on current earnings. It is valuing a future commercial outcome. At the supplied ¥6.81 billion market capitalization, and using the conservative ¥3.55 billion net-liquidity proxy from the unaudited FY2026 balance sheet, investors are effectively assigning roughly ¥3.3 billion of enterprise value to technology, pipeline, approvals, and future commercialization before allowing for further cash burn.

• One-time and timing factors: FY2026 revenue rose only 7.4% to ¥497.2 million despite two product-development milestones totaling ¥340 million. The product segment’s headline profitability therefore does not represent an established Medcle revenue stream. The ¥200 million Shionogi milestone due in FY2027 is also a one-off payment, not an indication of recurring earnings.
• Medium-term headwinds: Revenue moved from ¥530.7 million in FY2023 to ¥342.6 million in FY2024, ¥463.0 million in FY2025, and ¥497.2 million in FY2026. Operating results were losses in all four years: negative ¥48.3 million, ¥365.0 million, ¥299.5 million, and ¥330.2 million respectively. Revenue has grown over a multi-year period, but its composition is volatile and milestone-driven. Operating cash flow moved from positive ¥100.6 million in FY2023 to negative ¥230.8 million, negative ¥432.5 million, and negative ¥474.5 million in the following three years.
• Long-term commercial threat: Medcle’s reimbursement price is ¥24,100 per prescription. Management’s FY2027 operational goals are 1,000 adopting medical institutions and 2,000 monthly prescriptions. Simple arithmetic suggests that 2,000 monthly prescriptions at the gross reimbursement price would equate to approximately ¥578 million annually. This is an analyst calculation, not company guidance for SUSMED revenue or profit; the company has not disclosed the net revenue retained per prescription, achievement rate, persistence, or sales cost.

The market must therefore assume that Medcle adoption will prove materially stronger than currently disclosed, that SUSMED can sell effectively without Shionogi, and that later pipeline assets will produce milestones and royalties sufficient to absorb the research base. The evidence gap is substantial: there are no disclosed prescription volumes, active prescribers, patient persistence, customer-acquisition cost, gross margin on direct Medcle sales, or unit economics for the post-Shionogi sales model.

The company’s FY2027 guidance is not consistent with near-term self-funding. It forecasts 68.7% revenue growth but a ¥461 million operating loss. The market is paying for an option on a later inflection, not for earnings visible in the next fiscal year.

Temporary or Structural?

Loss of Shionogi distribution and milestones — structural but survivable. The damaged economic mechanism is commercial reach and risk transfer. Shionogi was a credible pharmaceutical counterparty that could have supplied sales infrastructure and milestone funding while SUSMED collected royalties. The termination removes both the sales-validation signal and the remaining conditional milestone stream. SUSMED can realistically replace a distributor or build direct commercialization within three years, but there is no evidence yet that it can do so at comparable speed or cost. Retaining 100% of future sales revenue is only better if sales volume and selling costs support it.

Insomnia-app adoption risk — structural but survivable. The damaged mechanism would be physician willingness to prescribe, patient engagement, and payer-supported economics. Software can be improved quickly; changing medical practice cannot. The problem is reversible within three years only if SUSMED demonstrates prescription growth, repeat use, and acceptable sales efficiency. The current lack of disclosed commercial KPIs makes this a genuine uncertainty rather than a temporary reporting issue.

Milestone-dependent revenue — structural. Milestones are lumpy by design, and an early-stage portfolio cannot be valued like a subscription software company. They can finance development but do not establish durable owner earnings. The remedy is a portfolio of launched products with royalties or recurring direct sales, not better quarterly presentation.

Platform commoditization — not truly structural yet, but a weak moat. SourceDataSync and the data-analysis tools may benefit from clinical-trial workflows, integrations, and evidence of auditability. Yet platform revenue was essentially flat year on year in FY2026, and there is no disclosed retention, pricing, or customer-concentration data. The absence of proof is not proof of failure, but it prevents a moat conclusion.

Cash burn and dilution — structural unless commercial proof arrives. FY2026 free-cash-flow outflow was ¥702.6 million, including ¥228.1 million of investing outflows. Dividing FY2026 cash of ¥3.70 billion by that full outflow gives a mechanical 5.3 years of funding. This is not a forecast: burn may fall if revenue scales or rise if development and commercialization accelerate. It does show that SUSMED has time, but not unlimited time. The 133,000 employee stock options issued in August 2026 represent about 0.8% of current shares before any future issuance; share-based compensation and future funding must be treated as part of the economic cost base.

Time-as-a-moat test: in two years, a well-funded competitor can build a broadly similar app and clinical-data platform, but may not match clinical evidence or reimbursement status. In five years, a competitor can plausibly complete clinical work and obtain approval if the market is attractive. In ten years, SUSMED’s advantage will depend less on original software and more on whether it has accumulated physician relationships, real-world outcomes data, distribution access, and a portfolio of reimbursed products. Those advantages are possible, but they are not yet demonstrated.

The central diagnosis is therefore ESSENCE with a time component. The immediate selloff was triggered by a discrete contract termination, but the deeper issue is structural: the original path from approval to scaled commercialization and milestone monetization is impaired. The cash reserve makes the company survivable; it does not restore the lost validation or prove that direct sales will work.

Is the Market Wrong? By How Much?

Moat-and-mispricing score: 2/10. SUSMED has real regulatory and clinical assets, but little evidence of a commercial moat, recurring owner earnings, or a self-funding growth model. The market may be underestimating the remaining cash and the option value of a successful Medcle launch, but it is already pricing an outcome substantially stronger than the disclosed operating record supports.

The supplied deterministic “worth-dead” evidence should be handled carefully. It puts FY2025 NCAV at ¥4.33 billion, or 63.6% of the supplied market capitalization. This is an archival FY2025 measure and not a current liquidation value. It excludes unavailable inputs such as short-term securities and interest-bearing debt, so it is not a complete cash valuation. The newer FY2026 unaudited balance sheet shows book value of ¥4.07 billion; the supplied market capitalization equates to 1.67 times that book value.

The supplied “worth-alive” owner-earnings estimate is negative ¥686.8 million for the stated FY2026 period, implying a negative 10.1% owner-earnings yield. It is a model estimate, not audited earnings, and has incomplete data mapping. Its precise amount should not be over-read, but its direction agrees with the official FY2026 free-cash-flow outflow of ¥702.6 million: the company currently consumes, rather than produces, owner earnings.

The following is an intrinsic-value framework based on FY2026 unaudited results, adjusted for the post-year-end Shionogi termination. It is not a price target. It uses the actual FY2026 issued share count of 16.868 million; it does not fully quantify dilution from all outstanding options, so per-share results may be modestly overstated.

The valuation is deliberately cash-led because a conventional earnings multiple is meaningless while owner earnings are negative. The bear case is not a formal liquidation appraisal; it is a conservative cash-and-runway outcome. The base and bull cases capitalize analyst-estimated normalized owner earnings, not management forecasts. They do not rely on multiple expansion.

The market’s implicit hurdle is demanding. After allowing for approximately ¥1.0 billion of further cash use and the present value of the confirmed ¥200 million milestone, the current ¥6.81 billion market capitalization requires roughly ¥4.1 billion of present-value operating value. That implies normalized annual owner earnings of approximately ¥540 million to ¥690 million in three years, depending on whether the required equity yield is 10% or 12%. This is well above the company’s FY2027 guidance of ¥838 million revenue and a ¥461 million operating loss.

The market therefore appears to be pricing something close to the bull outcome: successful Medcle adoption, controlled sales costs, a productive pipeline, and eventual high incremental margins. The observable evidence does not yet support that outcome. The market is not obviously wrong about the company having survival capital and upside optionality; it appears wrong only if one treats potential milestones, reimbursement approval, and a launch as equivalent to durable commercial earnings. On the disclosed data, the base intrinsic value is about 45% below current market value.

Key Facts, Estimates, and Judgments

Strongest falsification checks: the skeptical thesis would weaken if SUSMED discloses sustained monthly Medcle prescription growth, adoption approaching its 1,000-provider and 2,000-prescription-per-month targets, credible net revenue per prescription, low sales cost, and a new distribution partner on economically attractive terms. It would also weaken if the platform business begins to grow materially above its current ¥157 million revenue base with visible retention and margin data.

The thesis would strengthen if Medcle prescriptions remain low despite reimbursement, the company fails to replace Shionogi with a capable commercial partner, FY2027 losses exceed guidance, the cash burn accelerates, or further equity-linked compensation and financing materially dilute shareholders. The single most important missing evidence is not another pipeline announcement; it is repeatable, disclosed Medcle unit economics.